In the past 48 hours, the healthcare industry has seen several notable developments. The measles outbreak in Texas continues to grow, with 259 cases now reported, up from 223 just three days ago. Almost all cases are in unvaccinated individuals, highlighting ongoing public health challenges.

On the business front, Pfizer reported a 31% increase in U.S. sales of its migraine drug Nurtec last year, crediting a new direct phone line for doctors and patients to get insurance coverage help. This demonstrates how pharmaceutical companies are adapting strategies to boost sales in a competitive market.

In policy news, the Minnesota Attorney General reached a settlement with Mayo Clinic regarding charity care practices. The agreement requires Mayo to continue providing care to presumptively eligible patients and streamlines the application process, addressing concerns about medical debt and access to care for low-income patients.

The adoption of artificial intelligence in healthcare continues to accelerate. Companies like Hippocratic AI are introducing AI-powered virtual nurses to handle routine tasks, aiming to improve efficiency. However, this trend is facing pushback from human nurses concerned about job displacement and patient care quality.

A new study published in JAMA Health Forum questions the cost-effectiveness of blockbuster weight loss drugs like Wegovy and Zepbound. While these medications show health benefits, their high prices pose challenges for employers and government programs considering coverage.

Looking ahead, PwC projects an 8% increase in medical costs for employer-sponsored health plans in 2025, the highest growth rate in 13 years. This forecast reflects ongoing inflationary pressures and rising prescription drug spending.

The healthcare industry continues to grapple with staffing shortages, regulatory changes, and the integration of new technologies. Leaders are focused on improving affordability and access while navigating a complex landscape of innovation and cost pressures.